Table 4. Fixed health facilities for gambiense HAT: July 2019 survey.
Differences between the July 2019 survey and the June 2017 survey [2] in column ‘Δ’.
| Country | Diagnosis | Treatment | TOTAL | Δ | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DxC | DxS | DxP | DxPh | Total Dx | Δ | Tx1P | Tx2M | Tx2E | Tx2N | Total Tx | Δ | |||
| Angola | 130 | 130 | 27 | 21 | 130 | 70 | 21 | 6 | 21 | 16 | 21 | 1 | 130 | 70 |
| Benin | 3 | 3 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| Burkina Faso | 8 | 8 | 2 | 2 | 8 | 0 | 2 | 2 | 2 | 0 | 2 | 0 | 8 | 0 |
| Cameroon | 13 | 10 | 9 | 6 | 14 | 0 | 11 | 0 | 7 | 8 | 11 | 1 | 14 | 0 |
| Central African Republic | 15 | 4 | 5 | 5 | 15 | -4 | 10 | 3 | 3 | 7 | 10 | -3 | 15 | -4 |
| Chad | 52 | 52 | 7 | 7 | 52 | -48 | 53 | 3 | 9 | 9 | 53 | -47 | 53 | -47 |
| Congo | 68 | 68 | 6 | 4 | 68 | 3 | 3 | 0 | 3 | 3 | 3 | 0 | 68 | 3 |
| Côte d’Ivoire | 29 | 29 | 3 | 2 | 29 | 25 | 2 | 2 | 2 | 2 | 2 | 1 | 29 | 25 |
| Democratic Republic of the Congo | 696 | 578 | 276 | 231 | 696 | 64 | 546 | 59 | 145 | 191 | 546 | 82 | 799 | 76 |
| Equatorial Guinea | 4 | 4 | 2 | 1 | 4 | 0 | 4 | 1 | 1 | 1 | 4 | 1 | 4 | 0 |
| Gabon | 5 | 5 | 1 | 1 | 5 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 6 | 0 |
| Ghana | 10 | 10 | 0 | 0 | 10 | 2 | 10 | 0 | 0 | 0 | 10 | 2 | 10 | 2 |
| Guinea | 125 | 125 | 3 | 3 | 125 | 10 | 3 | 2 | 0 | 3 | 3 | 0 | 125 | 10 |
| Mali | 7 | 7 | 3 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 |
| Nigeria | 50 | 50 | 5 | 5 | 50 | 0 | 5 | 0 | 0 | 5 | 5 | 0 | 50 | 0 |
| South Sudan | 60 | 59 | 6 | 5 | 60 | 45 | 5 | 5 | 5 | 5 | 5 | 0 | 60 | 45 |
| Togo | 2 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Uganda | 48 | 48 | 12 | 4 | 48 | -86 | 4 | 4 | 4 | 4 | 4 | 0 | 48 | -86 |
| Total | 1,325 | 1,192 | 367 | 297 | 1,327 | 81 | 680 | 87 | 203 | 255 | 680 | 38 | 1,432 | 94 |
| Δ | 83 | 143 | 13 | 25 | 81 | 40 | 4 | -2 | 2 | 38 | 94 | |||
DxC: clinical diagnosis; DxS: serological diagnosis; DxP: parasitological diagnosis; DxPh: disease staging. Tx1P: treatment of first-stage infection with pentamidine; Tx2M: treatment of second-stage infection with melarsoprol; Tx2E: treatment of second-stage infection with eflornithine; Tx2N: treatment of second-stage infection with nifurtimox-eflornithine combination therapy (NECT). Differences between the July 2019 survey and the June 2017 survey [2] in column ‘Δ’.